Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
Feliu J, Garcia-Carbonero R, Capdevila J, Guasch I, Alonso-Orduna V, Lopez C, Garcia-Alfonso P, Castanon C, Sevilla I, Cerezo L, Conill C, Quintana-Angel B, Sanchez ME, Ghanem I, Martin-Richard M, Lopez-Gomez M, Leon A, Caro M, Fernandez T, Maurel J. Feliu J, et al. Among authors: sevilla i. Cancer Med. 2020 Feb;9(3):1008-1016. doi: 10.1002/cam4.2722. Epub 2019 Dec 18. Cancer Med. 2020. PMID: 31851776 Free PMC article. Clinical Trial.
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Jimeno A, Grávalos C, Escudero P, Sevilla I, Vega-Villegas ME, Alonso V, Juez I, García-Carbonero R, Bovio H, Colomer R, Cortés-Funes H. Jimeno A, et al. Among authors: sevilla i. Clin Transl Oncol. 2008 Jan;10(1):52-7. doi: 10.1007/s12094-008-0153-5. Clin Transl Oncol. 2008. PMID: 18208793 Clinical Trial.
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM. Maurel J, et al. Among authors: sevilla i. J Clin Oncol. 2009 Apr 10;27(11):1893-8. doi: 10.1200/JCO.2008.19.2930. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273704 Clinical Trial.
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.
Gravalos C, Salut A, García-Girón C, García-Carbonero R, León AI, Sevilla I, Maurel J, Esteban B, García-Rico E, Murias A, Cortés-Funes H. Gravalos C, et al. Among authors: sevilla i. Clin Transl Oncol. 2012 Aug;14(8):606-12. doi: 10.1007/s12094-012-0843-x. Epub 2012 Jul 19. Clin Transl Oncol. 2012. PMID: 22855138 Free PMC article. Clinical Trial.
Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E, Capdevila J, Castellano D, Jimenez-Fonseca P, Salazar R, Beguiristain-Gomez A, Alonso-Orduña V, Martinez Del Prado P, Villabona-Artero C, Diaz-Perez JA, Monleon A, Marazuela M, Pachon V, Sastre-Valera J, Sevilla I, Castaño A, Garcia-Carbonero R. Martin-Perez E, et al. Among authors: sevilla i. Neuroendocrinology. 2013;98(2):156-68. doi: 10.1159/000355152. Epub 2013 Sep 19. Neuroendocrinology. 2013. PMID: 23988576
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Castellano D, Capdevila J, Sastre J, Alonso V, Llanos M, García-Carbonero R, Manzano Mozo JL, Sevilla I, Durán I, Salazar R. Castellano D, et al. Among authors: sevilla i. Eur J Cancer. 2013 Dec;49(18):3780-7. doi: 10.1016/j.ejca.2013.06.042. Epub 2013 Sep 5. Eur J Cancer. 2013. PMID: 24012098 Clinical Trial.
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.
Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, Benavent M, Gomez J, Pastor MD, Chaves M, Suarez R, Paz-Ares L, de la Portilla F, Carranza-Carranza A, Sevilla I, Vicioso L, Garcia-Carbonero R. Molina-Pinelo S, et al. Among authors: sevilla i. BMC Cancer. 2014 Sep 7;14:656. doi: 10.1186/1471-2407-14-656. BMC Cancer. 2014. PMID: 25197016 Free PMC article.
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, Sevilla I, Escudero P, Sastre J, García-Donas J, Casanovas O, Earl J, Ortega L, Apellaniz-Ruiz M, Rodriguez-Antona C, Alonso-Gordoa T, Díez JJ, Carrato A, García-Carbonero R. Grande E, et al. Among authors: sevilla i. Ann Oncol. 2015 Sep;26(9):1987-1993. doi: 10.1093/annonc/mdv252. Epub 2015 Jun 10. Ann Oncol. 2015. PMID: 26063633 Free article. Clinical Trial.
142 results